| Literature DB >> 32622830 |
Fadi Fakhouri1, Moglie Le Quintrec2, Véronique Frémeaux-Bacchi3.
Abstract
In recent years, a substantial body of experimental and clinical work has been devoted to C3 glomerulopathy and Ig-mediated membranoproliferative glomerulonephritis. Despite the rapid accumulation of data, several uncertainties about these 2 rare forms of nephropathies persist. They concern their pathophysiology, classification, clinical course, relevance of biomarkers and of pathology findings, and assessment of the efficacy of the available therapies. The present review discusses the impact of these uncertainties on the clinical management of patients.Entities:
Keywords: C3 glomerulopathy; Ig-mediated membranoproliferative glomerulonephritis; complement
Mesh:
Substances:
Year: 2020 PMID: 32622830 DOI: 10.1016/j.kint.2020.05.053
Source DB: PubMed Journal: Kidney Int ISSN: 0085-2538 Impact factor: 10.612